| Endocardial Solutions Announces FDA Submission of Clarity Software May 9, 2000 MINNEAPOLIS / ST.PAUL -- Endocardial Solutions, Inc. (Nasdaq: ECSI) announced the submission of its next generation software, Clarity, to the U.S. Food and Drug Administration (FDA) as a 510(k). <*dv_6*>With a greatly streamlined user interface, Clarity software is designed to simplify use of the EnSite® 3000 System and cut training time for hospital staff. The software will be introduced in Europe through Endocardial Solutions' distribution partner Medtronic, Inc. (NYSE: MDT) and in the United States following regulatory approval anticipated this summer. <*dv_0*>"Our engineering team has worked tirelessly to develop this new product. We are very excited to be displaying Clarity at our booth at the NASPE meeting in Washington D.C. May 18-20," said Jim Bullock, president and CEO. "With Clarity software, we believe our existing and new customers will be able to use our EnSite 3000® System more intuitively and therefore more rapidly." Clarity reduces the number of mouse clicks required to move through the EnSite 3000® System by up to 70 percent. It also has tools to dramatically improve user orientation to the system's three-dimensional geometry. The U.S. Food and Drug Administration cleared the EnSite 3000® System for use in diagnostic mapping of complex arrhythmias in the right atrium of the heart during the second quarter 1999. Through a distribution agreement with Medtronic, Inc., the EnSite 3000® System and catheter have been available to electrophysiologists in Europe since the second quarter 1998. <*dv_2*>Based in St. Paul, Minnesota, Endocardial Solutions develops, manufactures and markets technology for diagnostic mapping of complex arrhythmias (abnormally rapid heartbeats caused by irregular electrical activity in the heart). The EnSite 3000® System provides a 3D graphical display of the heart's electrical activity. The discussion above contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. A number of factors should be considered in conjunction with these forward-looking statements. These factors are set forth in the cautionary statements included in Exhibit 99 to Endocardial Solutions' Form 10-K for the quarter ended December 31, 1999, filed with the Securities and Exchange Commission. Endocardial Solutions cautions investors and others to review the statements set forth in that report and that other factors may prove to be important in affecting the business and results of operations of Endocardial Solutions. Contacts: <*dv_1*>Leota Pearson, VP Finance & CFO, Endocardial Solutions
(651) 523-6933
lpearson@endocardial.com Perry Ketchum, Ketchum Metz Inc.
(763) 479-0145
pketchum@ketchummetz.com | 
